Standardized definitions of molecular response in chronic myeloid leukemia
Top Cited Papers
Open Access
- 16 April 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 26 (10), 2172-2175
- https://doi.org/10.1038/leu.2012.104
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CMLLeukemia Research, 2012
- Curing CML with imatinib—a dream come true?Nature Reviews Clinical Oncology, 2011
- Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Blood, 2010
- Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic PhaseJournal of Clinical Oncology, 2010
- Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing resultsBlood, 2006
- Discontinuation of imatinib therapy after achieving a molecular responseBlood, 2004
- Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer programLeukemia, 2003
- Chronic myeloid leukemia and interferon-α: a study of complete cytogenetic respondersBlood, 2001